Rivaroxaban For Suspension — FDA Drug Shortage
The FDA lists a drug shortage record for Rivaroxaban For Suspension from Janssen Pharmaceuticals with status To Be Discontinued. The shortage was first posted on Sep 18, 2026.
Shortage details
- Status
- To Be Discontinued
- Company
- Janssen Pharmaceuticals
- Package NDC
- 50458-575-01
- Presentation
- Xarelto, For Suspension, 155 mg (NDC 50458-575-01)
- Initial Posting
- Sep 18, 2026